Thermo Fisher microbiology business Acquired by Astorg | Healthcare M&A Deal

Astorg has acquired the Thermo Fisher microbiology business, a diagnostics imaging business in the United States, for $X. The acquired unit provides diagnostic consumables and equipment for antimicrobial susceptibility testing and culture media solutions, supporting clinical, pharmaceutical, and food safety laboratories. It operates under the Remel and Oxoid brands and serves thousands of labs across more than 100 countries, with recurring consumables driving over 95% of revenue. The platform acquisition is backed by Astorg, a pan-European private equity firm, and is structured as a standalone privately owned microbiology platform. The deal is subject to regulatory approvals and is expected to close in the second half of 2026, with Thermo Fisher continuing operations until completion.